<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p58" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_58{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_58{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_58{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_58{left:248px;bottom:1104px;letter-spacing:0.25px;}
#t5_58{left:143px;bottom:1047px;letter-spacing:-0.29px;}
#t6_58{left:250px;bottom:1067px;letter-spacing:-0.01px;}
#t7_58{left:250px;bottom:1047px;letter-spacing:-0.01px;}
#t8_58{left:250px;bottom:1028px;letter-spacing:-0.01px;}
#t9_58{left:248px;bottom:973px;letter-spacing:-0.04px;}
#ta_58{left:141px;bottom:902px;letter-spacing:-0.01px;}
#tb_58{left:248px;bottom:902px;letter-spacing:0.12px;}
#tc_58{left:141px;bottom:870px;letter-spacing:0.22px;}
#td_58{left:250px;bottom:865px;letter-spacing:-0.01px;}
#te_58{left:250px;bottom:845px;letter-spacing:-0.01px;}
#tf_58{left:250px;bottom:826px;letter-spacing:-0.01px;}
#tg_58{left:143px;bottom:822px;}
#th_58{left:141px;bottom:787px;letter-spacing:-0.03px;}
#ti_58{left:248px;bottom:787px;letter-spacing:-0.03px;}
#tj_58{left:141px;bottom:739px;letter-spacing:-0.28px;}
#tk_58{left:248px;bottom:712px;letter-spacing:-0.04px;}
#tl_58{left:141px;bottom:641px;letter-spacing:-0.01px;}
#tm_58{left:248px;bottom:641px;letter-spacing:0.12px;}
#tn_58{left:141px;bottom:609px;letter-spacing:0.22px;}
#to_58{left:250px;bottom:604px;letter-spacing:-0.01px;}
#tp_58{left:250px;bottom:584px;letter-spacing:-0.01px;}
#tq_58{left:143px;bottom:561px;}
#tr_58{left:141px;bottom:526px;letter-spacing:-0.03px;}
#ts_58{left:248px;bottom:526px;letter-spacing:-0.03px;}
#tt_58{left:141px;bottom:478px;letter-spacing:-0.28px;}
#tu_58{left:248px;bottom:451px;letter-spacing:-0.04px;}
#tv_58{left:141px;bottom:380px;letter-spacing:-0.01px;}
#tw_58{left:248px;bottom:380px;letter-spacing:0.12px;}
#tx_58{left:141px;bottom:348px;letter-spacing:0.22px;}
#ty_58{left:250px;bottom:343px;letter-spacing:-0.01px;}
#tz_58{left:250px;bottom:324px;letter-spacing:-0.01px;}
#t10_58{left:143px;bottom:300px;}
#t11_58{left:141px;bottom:265px;letter-spacing:-0.03px;}
#t12_58{left:248px;bottom:265px;letter-spacing:-0.03px;}
#t13_58{left:141px;bottom:217px;letter-spacing:-0.3px;}
#t14_58{left:248px;bottom:190px;letter-spacing:-0.04px;}
#t15_58{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_58{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_58{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_58{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_58{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_58{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_58{font-size:8px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts58" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg58Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg58" style="-webkit-user-select: none;"><object width="908" height="1286" data="58/58.svg" type="image/svg+xml" id="pdf58" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_58" class="t s0_58">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_58" class="t s1_58">58 </span>
<span id="t3_58" class="t s2_58">7.12. </span><span id="t4_58" class="t s0_58">Consensus-based recommendation </span>
<span id="t5_58" class="t s3_58">EEC </span>
<span id="t6_58" class="t s2_58">Radiochemotherapy should only be administered at facilities where acute toxicities caused </span>
<span id="t7_58" class="t s2_58">by radiotherapy or chemotherapy can be detected and adequately treated (facilities that </span>
<span id="t8_58" class="t s2_58">meet the relevant requirements of the certification for head and neck cancer centers). </span>
<span id="t9_58" class="t s4_58">Strong consensus: 95% </span>
<span id="ta_58" class="t s2_58">7.13. </span><span id="tb_58" class="t s1_58">Evidence-based recommendation </span>
<span id="tc_58" class="t s5_58">Recommendation level </span>
<span id="td_58" class="t s2_58">In patients with locally advanced laryngeal carcinoma (M0) who are not treated with surgery, </span>
<span id="te_58" class="t s2_58">primary chemoradiotherapy should be preferred to radiotherapy alone, especially in the age </span>
<span id="tf_58" class="t s2_58">group up to 70 years. </span>
<span id="tg_58" class="t s3_58">A </span>
<span id="th_58" class="t s4_58">Level of Evidence </span><span id="ti_58" class="t s4_58">[185, 186] </span>
<span id="tj_58" class="t s3_58">1a </span>
<span id="tk_58" class="t s4_58">Strong consensus: 100% </span>
<span id="tl_58" class="t s2_58">7.14. </span><span id="tm_58" class="t s1_58">Evidence-based recommendation </span>
<span id="tn_58" class="t s5_58">Recommendation level </span>
<span id="to_58" class="t s2_58">Primary radiochemotherapy should be performed with cisplatin-containing </span>
<span id="tp_58" class="t s2_58">chemotherapy administered simultaneously with radiotherapy. </span>
<span id="tq_58" class="t s3_58">A </span>
<span id="tr_58" class="t s4_58">Level of Evidence </span><span id="ts_58" class="t s4_58">[185, 186] </span>
<span id="tt_58" class="t s3_58">1a </span>
<span id="tu_58" class="t s4_58">Strong consensus: 100% </span>
<span id="tv_58" class="t s2_58">7.15. </span><span id="tw_58" class="t s1_58">Evidence-based recommendation </span>
<span id="tx_58" class="t s5_58">Recommendation level </span>
<span id="ty_58" class="t s2_58">If cisplatin is contraindicated, carboplatin +/- 5FU, mitomycin C +/- 5FU or cetuximab can </span>
<span id="tz_58" class="t s2_58">be administered in parallel with radiotherapy. </span>
<span id="t10_58" class="t s3_58">0 </span>
<span id="t11_58" class="t s4_58">Level of Evidence </span><span id="t12_58" class="t s4_58">[190-194] </span>
<span id="t13_58" class="t s3_58">1b </span>
<span id="t14_58" class="t s4_58">Strong consensus: 100% </span>
<span id="t15_58" class="t s0_58">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
